Article in European journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Ryan HuangDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Heyu ChenDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Jingjing XieDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Qi LouDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Lingxiao TanTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, Texas, USA.
Ningyan ZhangTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, Texas, USA.
Zhiqiang AnTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, Texas, USA.
Samuel JohnDepartment of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Cheng Cheng ZhangDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0003-4763-3887
Funding
UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Marcel Bernard Mettlen · 2010 to 2026
$53.7M
INTEGRATIVE IMMUNOLOGY TRAINING PROGRAMT32AI005284 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI Nan Yan · 2003 to 2026
$7.4M
ITIM-receptors for cancer treatmentR01CA248736 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI ZHANG, CHENGCHENG · 2020 to 2024
$2.9M
Reprogramming myeloid cells to inhibit cancer developmentR01CA263079 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI CHENGCHENG ZHANG · 2022 to 2026
$1.9M
Immune-Onc Therapeutics Inc. Sponsored Research GrantLeukemia and Lymphoma Society 6629-21National Cancer Institute, National Institutes of Health 5P30CA142543National Cancer Institute, National Institutes of Health R01CA248736National Cancer Institute, National Institutes of Health R01CA263079NCI NIH HHS P30 CA142543NCI NIH HHS R01 CA248736NCI NIH HHS R01 CA263079NIAID NIH HHS T32 AI005284U.S. Department of Defense ME190050
6 · The paper itself
Abstract
Chimeric antigen receptor-T cell (CAR-T) immunotherapy has shown remarkable results for the treatment of certain hematologic malignancies. A redirection strategy that utilizes clinically relevant CAR-T cells in combination with adapter proteins may be an effective strategy to target other hematologic and solid cancers. We established a fusion antibody-based strategy with flexibility to target multiple tumor types in combination with a novel anti-leukocyte immunoglobulin-like receptor-B 4 (LILRB4) CAR-T cell. Specifically, we engineered switch protein (SwP) adapters containing the LILRB4 extracellular domain fused to either an anti-CD19 or anti-CD20 single-chain variable fragment (scFv). These SwPs were sufficient to stimulate anti-LILRB4 CAR-T cells against SwP-tagged LILRB4
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
A Switch Protein Adapter for Anti-LILRB4 CAR-T Cells. · full record | Socratic